Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 738.26

-1.2%

3:12 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (914)	3/9/2004 7:38:33 PM
From: Miljenko Zuanic	Read Replies (2) of 3559

Thnx Wilder. <<Does TRAP trap this rascal?>> Yes, according to REGN (and publications). Because Trap is composed of the both receptor fragments (R1 and R2), it trap with equal potency (very small difference) all VEGF-A isoforms (121 to 198 fragment). It is known that VEGF-A (121 and 164) is pro-inflammatory, and it does not phosphorylate and activate R2 well (it does not promote angiogenesis, but it does bind to R2 so it somehow neutralize this receptor), or it is weak angiogenic antagonist. It appears that in wet AMD both, inflammatory and angiogenic components, are important. Maybe systemic (iv) Trap can penetrate OBB (due to capillary likeness) and suppress local VEGF action, not only trap and neutralize circulating VEGF. Will see, in +12 months. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next